Interleukin-1α Activity in Necrotic Endothelial Cells Is Controlled by Caspase-1 Cleavage of Interleukin-1 Receptor-2

IMPLICATIONS FOR ALLOGRAFT REJECTION*

Received for publication, May 28, 2015, and in revised form, August 19, 2015 Published, JBC Papers in Press, August 31, 2015, DOI 10.1074/jbc.M115.667915

Laura C. Burzynski, Melanie Humphry, Martin R. Bennett, and Murray C. H. Clarke

From the Division of Cardiovascular Medicine, University of Cambridge, Level 6, Box 110, Addenbrooke’s Hospital, Cambridge CB2 0QQ, United Kingdom

Background: IL-1α released from damaged endothelial cells (ECs) drives inflammation and chronic graft rejection. How ECs activate IL-1α is unknown.

Results: Generation of active IL-1α in ECs requires caspase-1 proteolysis of an inhibitory complex that releases IL-1α and enables calpain cleavage to the mature cytokine.

Conclusion: IL-1α is controlled post-translationally in ECs.

Significance: Multiple targets exist to prevent IL-1α activation during disease.

Inflammation is a key instigator of the immune responses that drive atherosclerosis and allograft rejection. IL-1α, a powerful cytokine that activates both innate and adaptive immunity, induces vessel inflammation after release from necrotic vascular smooth muscle cells (VSMCs). Similarly, IL-1α released from endothelial cells (ECs) damaged during transplant drives allograft rejection. However, IL-1α requires cleavage for full cytokine activity, and what controls cleavage in necrotic ECs is currently unknown. We find that ECs have very low levels of IL-1α activity upon necrosis. However, TNFα or IL-1 induces significant levels of active IL-1α in EC necrotic lysates without alteration in protein levels. Increased activity requires cleavage of IL-1α by calpain to the more active mature form. Immunofluorescence and proximity ligation assays show that IL-1α associates with interleukin-1 receptor-2, and this association is decreased by TNFα or IL-1 and requires caspase activity. Thus, TNFα or IL-1 treatment of ECs leads to caspase proteolytic activity that cleaves interleukin-1 receptor-2, allowing IL-1α dissociation and subsequent processing by calpain. Importantly, ECs could be primed by IL-1α from adjacent damaged VSMCs, and necrotic ECs could activate neighboring normal ECs and VSMCs, causing them to release inflammatory cytokines and up-regulate adhesion molecules, thus amplifying inflammation. These data unravel the molecular mechanisms and interplay between damaged ECs and VSMCs that lead to activation of IL-1α and, thus, initiation of adaptive responses that cause graft rejection.

Chronic transplant allograft rejection is the leading cause of late graft failure and mortality. Rejection is most commonly caused by graft arteriosclerosis (chronic allograft vasculopathy), which occurs due to a host immune alloreponse directed against the graft blood vessels (1). Allograft vasculopathy is characterized by progressive stenosis of vessels throughout the organ due to deposition of extracellular matrix, VSMC proliferation, and constrictive remodeling that occurs over months to years. Vessel stenosis leads to ischemia, which is thought to be the primary cause of parenchymal fibrosis within the tissue, loss of function, and graft failure. Late graft failure occurs at a rate of 5% per year post transplantation in the main solid organ transplants (kidney, heart, liver) (1) and is currently untreatable. Graft ECs expressing MHC molecules are a major target of this alloresponse, causing activation of CD4 memory T cells and IFNγ production that is vital for arteriosclerosis (2). In addition, other non-immune mechanisms also modulate the development of arteriosclerosis.

Grafts are exposed to both physical and ischemic injuries during the pre- and perioperative period. In particular, cadaveric donor grafts fail at accelerated rates, which may be due to the greater injury they receive. The two main theories of why injury drives graft failure are the “burden of injury hypothesis” (3) and the “immune modulation hypothesis” (1). The former postulates that grafts are exposed to multiple other injuries such as periods of acute rejection, chronic rejection, and other insults and can only tolerate a finite amount before the graft fails. Thus, grafts exposed to more perioperative injury simply exceed this limit earlier. The latter proposes that early graft injury somehow alters a graft such that it interacts with the host’s immune system in a way that accelerates rejection. The two theories are likely linked, with graft damage driving cell proliferation in the vessel wall as a typical response to injury and

* This work was supported by British Heart Foundation (BHF) Grants FS/09/005/26845, FS/13/3/30038 and FS/11/77/29327 (to M. C. H. C.) & RG/13/14/30314 (to M. R. B.); the BHF Cambridge Centre for Cardiovascular Research Excellence; and the National Institute for Health Research Cambridge Biomedical Research Centre. The authors declare that they have no conflicts of interest with the contents of this article.

**Author’s Choice**—Final version free via Creative Commons CC-BY license.

1 To whom correspondence should be addressed. Tel.: 01223-762581; Fax: 01223-331505; E-mail: mchc2@cam.ac.uk.

© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.

The abbreviations used are: VSMC, vascular smooth muscle cell; EC, endothelial cell; IL-1R2, interleukin-1 receptor-2; DAMP, damage-associated molecular pattern; Th17, helper cell 17; HUVEC, human umbilical vein endothelial cell; pAb, polyclonal antibody.
injured necrotic cells acting as a potent source of damage-associated molecular patterns (DAMPs) that directly stimulate innate and adaptive immune cells. DAMPs are typically molecules that are exclusively intracellular under normal conditions and, thus, their presence outside the cytosol indicates cell damage and/or necrosis. Identified DAMPs include high-mobility group box 1, ATP, heat shock proteins, actin, uric acid, DNA, and IL-1α (5). IL-1α is released from necrotic ECs and is particularly important in graft rejection as it drives IL-17 and IFNγ production from infiltrating memory CD4+ T cells (6,7), which are two cytokines of key significance in enhanced alloimmunity.

IL-1α binds to the type 1 IL-1 receptor (IL-1R1) and recruits IL-1 receptor accessory protein to form a complex that interacts with the signaling adapter MyD88 (8). Following a phospho-signaling cascade, NF-κB is activated, inducing expression of multiple proinflammatory genes (8). IL-1α is known to be fully biologically active, and thus release from damaged ECs enables it to act as a universal danger signal or “alarmin.” However, recent work has shown that pro-IL-1α has far less cytokine activity than the calpain-cleaved mature form and acts as a partial agonist due to low binding affinity for IL-1R1 (9,10). Furthermore IL-1α activity after necrosis is regulated in a cell type-specific manner with most cells unable to cleave IL-1α upon necrosis and, therefore, contain no IL-1α activity (10). IL-1α released from damaged ECs drives the TH helper 17 cell (Th17) responses that induce vessel arteriosclerosis and subsequent allograft rejection (6,7), suggesting that ECs must be able to activate pro-IL-1α. However, whether ECs constitutively express IL-1α, what causes cleavage and/or activation of IL-1α and the mechanism controlling this is not known. We find that IL-1α activity is regulated via a novel mechanism involving TNFα- and IL-1-induced caspase activity that cleaves IL-1R2, causing IL-1α dissociation that enabled subsequent processing by calpain.

**Experimental Procedures**

**Tissue Culture**—All material was from Sigma unless stated otherwise. Human umbilical vein ECs (HUVECs) were cultured in large vessel endothelial cell media with supplements (all TCS Cellworks), human aortic VSMCs and HeLa cells were cultured in DMEM, 10% FCS, 10 units/ml penicillin, 10 mg/ml streptomycin, 5 mg/ml l-glutamine, and all were passaged at 80% confluency. EL4 and THP1 cells were cultured in RPMI, 10% FCS, 10 units/ml penicillin, 10 mg/ml L-glutamine, and all were passaged at 80% confluence.

**Cytokine Measurement**—Clarified supernatants were analyzed by ELISA for IL-1α and IL-2 (both Peprotech), or cytometric bead ELISA for IL-6, IL-8, and MCP-1 (eBioscience) as per the manufacturer’s instructions. Plates were measured at 450 nm on a spectrophotometer (GenS) with the data analyzed using a 4-parameter logistic standard curve. Beads were measured by cytometry (Accuri C6), and data were analyzed with FlowCytomix Pro (eBiosciences).

**RT-PCR and Quantitative PCR**—RNA was isolated using TRIzol reagent and DNase-treated (Ambion) before reverse transcription with MMLV and oligo(dT) (Promega). Quantitative PCR used TaqMan probe/primers with AmpliTaq gold (Life Technologies) in a RotorGene thermocycler (Corbett). Analysis utilized standard curves with specific expression level normalized to GUSB and TBP. IL-1R2 transcript was assessed by RT-PCR using the primers: soluble IL-1R2 forward (TGTCCTCCAAAAG-GAAGAGCGA); membrane IL-1R2 forward (ACACGGATGGAAGTCAGCCACA); GAPDH forward (TGGGCCCAGGA) and reverse (GTGAAAGTGGGGCCAGAG); and reverse (CTCCAGGACTGACCTCAGCG). Western Blotting—Western Blotting was performed as previously described with lysis of cells directly in Laemml buffer, SDS-PAGE, and transfer onto PVDF membrane. After blocking (5% milk, membranes were incubated (4 °C; 16 h) with IL-1α pAb (1:500; Peprotech), IL-1R2 pAb (1:250; R&D), or β-actin mAb (1:5000; Sigma) before washing (PBS/Tween) and incubation (room temperature for 1 h) with anti-rabbit HRP (1:2000; GE Healthcare) or anti-goat HRP (1:2000; Jackson ImmunoResearch). After washing membranes were visualized with ECL reagent (Amersham Biosciences) and x-ray film (FujiFilm).

**IL-1R2 Protection Assay**—Necrotic HUVEC lysates from either control or IL-1β-treated cells were incubated with increasing amounts of His-tagged pro-IL-1α (0–250 ng) and incubated (37 °C; 1 h) before the addition of 3× Laemml buffer, boiling, and analysis by Western blotting.

**Calpain Activity**—Calpain activity was assayed using the luminescent CalpainGlo kit (Promega). Test sample and reagents were mixed 50:50 and incubated (room temperature; 10 min) before analysis on a luminometer (Turner Biosystems).

**Immunofluorescence and Proximity Ligation Assay**—HUVECs adhered to coverslips were treated as indicated before fixation


IL-1R2 Controls IL-1α Activity in Necrotic Endothelial Cells

**Results**

IL-1α Activity in Necrotic Endothelial Cells Is Controlled Independently of Protein Level—IL-1α derived from injured donor ECs is required for intimal T cell recruitment and IL-17 production in graft allopathy (6, 7), suggesting that ECs must be able to activate IL-1α upon necrosis. We first examined necrotic HUVEC lysates for IL-1α activity using an EL4 cell bioassay in which IL-2 is produced in an IL-1-dependent manner. EL4 cells display very high sensitivity to IL-1, responding to femtomolar concentrations. Treatment of EL4 cells with necrotic VSMC lysates as a positive control (10) resulted in high levels of IL-2 production (~8000 ± 200 pg/ml) (Fig. 1A), which was shown to be IL-1α-dependent with a neutralizing antibody. However, necrotic HUVEC lysates induced minimal IL-2 release, similar to HeLa and THP1 necrotic lysates (~300 ± 25 pg/ml) (Fig. 1B). HeLa and THP-1 cells have previously been shown to contain negligible IL-1α activity after necrosis (10), suggesting that ECs are unable to activate IL-1α upon necrosis. However, despite comparable levels of IL-1α activity between the cell types, Western blot showed that HUVECs contain ~10% of the IL-1α protein observed in THP1 and HeLa cells (Fig. 1C). This indicates that IL-1α protein expression in HUVEC necrotic lysates is not predictive of IL-1α activity, suggesting that another mechanism regulates IL-1α activity in ECs. Due to the high sensitivity of the EL4 bioassay, IL-1α activity in necrotic HUVEC lysates was reassessed using HeLa cells, which release IL-6 more linearly in response to IL-1 (10). Necrotic HUVEC lysates induced similar activity to the negative control.
(Fig. 1D). However, pretreatment of ECs with TNFα or IL-1β before making necrotic lysates resulted in a large increase in IL-1α-specific activity. Together these data suggest that unstimulated HUVECs contain minimal amounts of IL-1α activity but that this can be increased by activation of the cell before necrosis.

**Increased IL-1α Activity in Activated ECs Occurs Due to IL-1α Cleavage by Calpain**—The increase in IL-1α activity seen in necrotic HUVECs after IL-1 or TNFα treatment could be due to increased IL-1α protein, increased IL-1α cleavage, or loss of an IL-1 antagonist. We, therefore, examined IL-1α mRNA in HUVECs treated with TNFα or IL-1. Although activated HUVECs had increased IL-1α transcripts compared with control cells (Fig. 2A), IL-1α protein levels were similar by Western blotting (Fig. 2B) or intracellular cytokine staining and flow cytometry (Fig. 2C), confirming that IL-1α activity is not correlated to IL-1α protein expression. Calpain cleavage of pro-IL-1α during necrosis significantly increases activity. As necrotic EC lysates contain calpain activity comparable with other cell types that were not altered by TNFα or IL-1β treatment (Fig. 2D), we investigated whether EC activation resulted in more IL-1α processing using a cleaved IL-1α-specific ELISA (Fig. 2, E and F). Pretreatment of ECs with TNFα or IL-1β before necrosis significantly increased cleaved IL-1α activity compared with control (Fig. 2G), which was inhibited by the calpain-specific inhibitor calpeptin (Fig. 2G). Thus, the increased IL-1α activity in necrotic EC lysates after activation is due to increased IL-1α cleavage and not increased IL-1α protein.

**IL-1α Binding to IL-1R2 Prevents Calpain Cleavage and Controls Cytokine Activity in ECs**—IL-1α activity can be regulated by an intracellular form of IL-1R2 that protects pro-IL-1α from calpain cleavage (10). HUVECs expressed transcripts for both the membrane-bound and soluble forms of IL-1R2 (Fig. 3A), whereas immunofluorescence revealed pro-IL-1α and IL-1R2 to be highly co-localized (Fig. 3B). Although co-localization by immunofluorescence suggests association, it does not prove binding. However, an in situ proximity ligation assay (DuoLink) revealed that IL-1α and IL-1R2 are physically associated in control ECs (Fig. 3C). As IL-1R2 binding protects IL-1α from calpain cleavage, a general reduction in the steady state level of IL-1R2 protein could allow more processing and activation of IL-1α upon necrosis. However, TNFα or IL-1β treatment did...
IL-1R2 Controls IL-1α Activity in Necrotic Endothelial Cells

FIGURE 3. IL-1α binding to IL-1R2 prevents calpain cleavage and controls cytokine activity in ECs. A, RT-PCR for membrane (mIL-1R2) and soluble (sIL-1R2) IL-1R2 and GAPDH transcript within THP1 and HUVEC cells. B, dual immunofluorescence for pro-IL-1α and IL-1R2 in control HUVECs. Scale bars represent 50 μm. C, proximity ligation assay (DuoLink) showing association between IL-1α and IL-1R2 in control HUVECs. D, Western blot for IL-1R2 in whole cell lysates of HUVECs pretreated as indicated. E, mean fluorescent intensity (MFI) minus isotype control of HUVEC cells, pretreated as indicated, stained for IL-1R2, and analyzed by flow cytometry. Data represent the mean ± S.E. of n = 2.

not affect IL-1R2 protein levels on Western blotting (Fig. 3D) or flow cytometry (Fig. 3E).

EC Activation Reduces the Interaction between IL-1α and IL-1R2—Most cell types have excess IL-1R2 that can protect exogenously added pro-IL-1α from calpain cleavage. Thus, by incubating necrotic EC lysates with increasing concentrations of exogenous pro-IL-1α and measuring the amount of uncleaved pro-IL-1α, we can determine the amount of “competent” IL-1R2. This showed that necrotic lysates from HUVECs prestimulated with IL-1β were less able to protect exogenous pro-IL-1α against cleavage compared with control lysates (Fig. 4A). This supports that activated ECs have more cleaved IL-1α (Fig. 2G) because IL-1R2 is less able to protect it from calpain cleavage. To confirm this, IL-1α/IL-1R2 association was quantified with DuoLink, which visually showed decreased association after TNFα and IL-1β treatment (Fig. 4B). Blinded interaction counts per cell confirmed this decrease (Fig. 4C), as did DuoLink performed in suspension quantified by FACS (Fig. 4D). Together these data suggest that IL-1α activity increases in pretreated necrotic EC lysates due to a reduction in IL-1R2/IL-1α association that subsequently allows IL-1α processing by calpain to the more active mature form.

Caspase-1 Cleavage of IL-1R2 Enables Induction of IL-1α Activity in Stimulated ECs—IL-1R2 cleavage by caspase-1 is reported to cause its disassociation from pro-IL-1α, which subsequently enables calpain cleavage and activation (10). As no significant change in IL-1R2 protein level was found (Fig. 3, D and E), we postulated that caspase-1 cleavage of IL-1R2 could be responsible for the decreased association with IL-1α seen after EC stimulation. HUVECs were treated concurrently with TNFα and the pan-caspase inhibitor ZVAD-fluoromethyl ketone or the caspase-1-specific inhibitor YVAD-fluoromethyl ketone. Both inhibitors significantly reduced TNFα-induced IL-1α activity seen in necrotic lysates (Fig. 5A). Importantly, as all TNFα-induced IL-1 activity was IL-1α-specific, this excludes any effect of caspase inhibition on IL-1β activation. To confirm that caspase action increased IL-1α activity by promot-

FIGURE 4. EC activation reduces the interaction between IL-1α and IL-1R2. A, Western blot for IL-1α in necrotic HUVEC lysates, pretreated as indicated, and incubated with increasing quantities of exogenous pro-IL-1α (p33). B, proximity ligation assay (DuoLink) showing association between IL-1α and IL-1R2 in HUVEC cells pretreated as indicated. C and D, relative number of interactions between IL-1α and IL-1R2 in HUVECs pretreated as indicated, assessed by DuoLink and quantified by blinded counting (C) and flow cytometry (D). MFI, mean fluorescent intensity. Data represent the mean ± S.E. of n = 2, * p ≤ 0.05.
E-selectin and intercellular adhesion molecule 1 (ICAM-1; Fig. 6, D–F). Together these data indicate that interplay between damaged VSMCs and ECs could initiate activation of IL-1α in ECs, which in turn can activate adjacent vessel wall cells to effectively amplify inflammation.

Discussion

Immune system activation protects organisms from pathogens able to challenge host fitness, usually by detecting pathogen-associated molecular patterns that are recognized as non-self by innate immune cells. However, immune activation also occurs without infection as a vital means of dealing with physical insults such as trauma, burns, tissue anoxia, or cytotoxic chemicals. This sterile inflammation is instigated by host-derived factors known as damage-associated molecular patterns that usually reside intracellularly but are released after cell damage. Conversely, immune activation by these endogenous factors also drives diseases such as arthritis, atherosclerosis, and graft rejection. Although IL-1α released from damaged ECs drives immune responses that cause arteriosclerosis and graft failure (6, 7), what controls IL-1α activity in ECs is unknown.

We find that unstimulated ECs constitutively express small amounts of IL-1α protein but that it has no activity upon release from damaged cells. However, after prior activation with TNFα or IL-1, necrotic EC lysates show significantly increased IL-1α activity without any increase in IL-1α protein. Necrotic lysates made from unstimulated ECs contain only pro-IL-1α, whereas stimulated necrotic EC lysates contain calpain-cleaved mature IL-1α, which is much more active. Unstimulated ECs have cytosolic IL-1α that is co-localized and associated with IL-1R2, which protects it from calpain cleavage and activation. Stimulated ECs show reduced IL-1α/IL-1R2 interaction due to caspase cleavage of IL-1R2, which causes complex disassociation and enables calpain to cleave pro-IL-1α. Unstimulated ECs can be primed by damaged adjacent VSMCs that natively contain active IL-1α, whereas necrotic EC lysates from stimulated cells cause cytokine release and adhesion receptor up-regulation in adjacent viable VSMCs and ECs, thereby amplifying inflammation (outlined in Fig. 7). Thus, interplay between damaged ECs and other vessel wall cells leads to IL-1α activation that can drive subsequent Th17 responses and drive graft rejection.

IL-1 is a likely candidate to drive graft failure, as it can both induce inflammation and activate adaptive immunity. Indeed, inhibition of IL-1 signaling with IL-1RA or sIL-1R1 promotes survival in cardiac allografts (13), corneal grafts (14), and islet cell transplants (15) and also reduces graft versus host disease after bone marrow transplant (16). Furthermore, components of the inflammasomes upstream of IL-1 activation also show up-regulation during graft rejection (17). Although we currently do not understand how an intracellular form of IL-1R2 is expressed, it is present inside multiple cell types (10) including ECs. Using adenovirus-mediated transfer of sIL-1R2 to endothelial cells within cardiac allografts, Simeoni et al. (18) found decreased CD4+ cell infiltration and significantly increased graft survival, again supporting inhibition of IL-1 as a means of preventing graft rejection. IL-1 signaling typically results in production of IL-6, MCP-1, and IL-8. In particular, IL-1 and
IL-6 strongly promote Th17 differentiation of T cells (19) and the subsequent IL-17 production that drives rejection (20). Furthermore, although MCP-1 is considered a classic chemokine for monocytes, it is also a powerful T cell chemoattractant (21). Indeed, Rao (7) reported significantly decreased T cell recruitment and IL-17 production in vivo after IL-1 blockade during vessel allograft rejection.

IL-1α is rarely found outside cells or in the circulation without cell death and as such has been described as an Alarmin, i.e. an endogenously derived DAMP. Although still contested (22), we and others find that IL-1α requires cleavage for full activity, with the proform showing low receptor affinity (9, 10). Although EC-derived IL-1α drives allograft rejection, our data show that IL-1α is uncleaved and inactive in unstimulated ECs due to its association with IL-1R2. ECs need an initial “insult” to generate active IL-1α such as pretreatment with TNFα or IL-1, which leads to the caspase-dependent release of IL-1R2 from pro-IL-1α. Caspase-1 is normally activated by the supramolecular inflammasomes that typically require an initial signal through Toll-like receptors (e.g. LPS) followed by a second stimulus (e.g. ATP, crystalline material) that leads to caspase-1 activation (23). However, some cell types only require the first toll-like receptor signal to activate caspase-1 (e.g. monocytes) (24). Therefore, as IL-1R1 and toll-like receptors share the same TIR domain and signaling pathway, IL-1 stimulation functionally equates to toll-like receptor ligation and thus could lead to caspase-1 activation in ECs. Two independent lines of evidence support the involvement of caspase-1 in this process; first, use of either a pan- or caspase-1-specific inhibitor reduces IL-1α activation after necrosis; second, expression of IL-1R2 with a mutation in the specific caspase-1 cleavage site acts as a dominant negative in ECs, resulting in less activation of IL-1α after necrosis. Interestingly, despite activation of caspase-1, we see no evidence of IL-1α activity in necrotic EC lysates, suggesting that ECs either do not express pro-IL-1α or that it is compartmentalized away from the caspase-1 activity.

These and previous data (6, 7) also suggest that the burden of injury hypothesis (3) and the immune modulation hypothesis (1) of graft rejection cannot be mutually exclusive. Necrotic ECs cannot activate IL-1α without initial damage to vessels that cause release of active IL-1α from VSMCs or other sources, However, once primed, ECs can subsequently activate IL-1α.
IL-1R2 Controls IL-1α Activity in Necrotic Endothelial Cells

Upon necrosis and in addition up-regulate adhesion molecules such as intercellular adhesion molecule 1 and E-selectin, leading to recruitment of leukocytes. Within this milieu of IL-1α and IL-1-induced cytokines CD4 memory T cells will be pushed toward the Th17 lineage with production of IL-17 and instigate arteriosclerosis and graft rejection. This modulation of adaptive immunity can cause destruction of vascular wall cells and acute rejection. However, although effective immunosuppression prevents this acute response, chronic rejection still occurs, with progressive stenosis due to neointimal expansion causing tissue ischemia. Innumerable factors have been described to cause VSMC migration and proliferation in multiple models of neointima formation; however, what growth factors or cytokines cause this during graft arteriosclerosis is poorly understood. Interestingly, as the pathological changes remain confined to the donor tissue (literally stopping at the suture lines) and do not affect the host vasculature (25), this suggests that neointimal formation is dependent on cell-cell interactions rather than soluble mitogenic factors.

In conclusion, our data show that although EC-derived IL-1α is key in driving graft arteriosclerosis, it is inactive in unstimulated ECs due to binding to IL-1R2. ECs need priming via IL-1α derived from damaged VSMCs or TNFα to enable IL-1α activation upon necrosis, which leads to caspase-1-mediated cleavage of IL-1R2 and complex disassociation. In addition, necrotic EC-derived IL-1α causes inflammatory cytokine production and adhesion molecular up-regulation by adjacent ECs and VSMCs. These data help clarify the complex interplay between cell types in perioperatively damaged vessels that lead to IL-1-driven adaptive immunity and subsequent rejection. In addition, these data suggest that inhibition of inflammasomes, caspase-1, calpain, or IL-1α are potential therapeutic candidates to prevent arteriosclerosis and allograft rejection.

Author Contributions—M. C. H. C. conceived and coordinated the study and wrote the paper. L. C. B. designed, performed, and analyzed the experiments. M. H. provided technical assistance and produced recombinant proteins. M. R. B. critically revised the manuscript for important intellectual content. All authors analyzed the results and approved the final version of the manuscript.

References
1. Libby, P., and Pober, J. S. (2001) Chronic rejection. *Immunity* 14, 387–397
2. Tellides, G., Tereb, D. A., Kirkiles-Smith, N. C., Kim, R. W., Wilson, J. H., Schechner, J. S., Lorber, M. I., and Pober, J. S. (2000) Interferon-γ elicits arteriosclerosis in the absence of leukocytes. *Nature* 403, 207–211
3. Halloran, P. F., Homik, J., Goes, N., Lui, S. L., Urmon, J., Ramassar, V., and Cockfield, S. M. (1997) The "injury response": a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes. *Transplant Proc.* 29, 79–81
4. Kono, H., and Rock, K. L. (2008) How dying cells alert the immune system to danger. *Nat. Rev. Immunol.* 8, 279–289
5. Zheng, Y., Gardner, S. E., and Clarke, M. C. (2011) Cell death, damage-associated molecular patterns, and sterile inflammation in cardiovascular disease. *Arterioscler. Thromb. Vasc. Biol.* 31, 2781–2786
6. Rao, D. A., Tracey, K. J., and Pober, J. S. (2007) IL-1α and IL-1β are endogenous mediators linking cell injury to the adaptive alloimmune response. *J. Immunol.* 179, 6536–6546
7. Rao, D. A., Eid, R. E., Qin, L., Yi, T., Kirkiles-Smith, N. C., Tellides, G., and Pober, J. S. (2008) Interleukin (IL)-1 promotes allogepic T cell intimal infiltration and IL-17 production in a model of human artery rejection. *J. Exp. Med.* 205, 3145–3158
8. Dinarello, C. A. (2009) Immunological and inflammatory functions of the interleukin-1 family. *Annu. Rev. Immunol.* 27, 519–550
9. Afonina, I. S., Tynan, G. A., Logue, S. E., Cullen, S. P., Bots, M., Lüthi, A. U., Reeves, E. P., McElvaney, N. G., Medema, J. P., Lavelle, E. C., and Martin, S. J. (2011) Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1α. *Mol. Cell* 44, 265–278
10. Zheng, Y., Humphry, M., Maguire, J. J., Bennett, M. R., and Clarke, M. C. (2013) Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1α, controlling necrosis-induced sterile inflammation. *Immunity* 38, 285–295
11. Imaiizumi, T., Itaya, H., Fujita, K., Kudoh, D., Kudoh, S., Mori, K., Fujimoto, K., Matsumiya, T., Yoshida, H., and Satoh, K. (2000) Expression of tumor necrosis factor-α in cultured human endothelial cells stimulated with lipopolysaccharide or interleukin-1α. *Arterioscler. Thromb. Vasc. Biol.* 20, 410–415
12. Pober, J. S., Bevilacqua, M. P., Mendrick, D. L., Lapierre, L. A., Fiers, W., and Gimbrone, M. A., Jr. (1986) Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. *J. Immunol.* 136, 1680–1687
13. Fanslow, W. C., Sims, J. E., Sassenfeld, H., Morrissey, P. J., Gillis, S., Dower, S. K., and Widmer, M. B. (1990) Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. *Science* 248, 739–742
14. Yamada, J., Dana, M. R., Zhu, S. N., Alard, P., and Streilein, J. W. (1998)
IL-1R2 Controls IL-1α Activity in Necrotic Endothelial Cells

Interleukin 1 receptor antagonist suppresses allosensitization in corneal transplantation. *Arch. Ophthalmol.* **116**, 1351–1357

15. McCall, M., Pawlick, R., Kin, T., and Shapiro, A. M. (2012) Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice. *Am. J. Transplant.* **12**, 322–329

16. McCarthy, P. L., Jr., Abhyankar, S., Neben, S., Newman, G., Sieff, C., Thompson, R. C., Burakoff, S. J., and Ferrara, J. L. (1991) Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. *Blood* **78**, 1915–1918

17. Seto, T., Kamijo, S., Wada, Y., Yamaura, K., Takahashi, K., Komatsu, K., Otsu, Y., Terasaki, T., Fukui, D., Amano, J., Taniguchi, S., Sagara, J., and Ito, K. (2010) Upregulation of the apoptosis-related inflammasome in cardiac allograft rejection. *J Heart Lung Transplant* **29**, 352–359

18. Simeoni, E., Dudler, J., Fleury, S., Li, J., Pagnotta, M., Pascual, M., von Segesser, L. K., and Vassalli, G. (2007) Gene transfer of a soluble IL-1 type 2 receptor-Ig fusion protein improves cardiac allograft survival in rats. *Eur. J. Cardiothorac. Surg.* **31**, 222–228

19. Chung, Y., Chang, S. H., Martinez, G. J., Yang, X. O., Nurieva, R., Kang, H. S., Ma, L., Watowich, S. S., Jetten, A. M., Tian, Q., and Dong, C. (2009) Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. *Immunity* **30**, 576–587

20. Antonyamy, M. A., Fanslow, W. C., Fu, F., Li, W., Qian, S., Troutt, A. B., and Thomson, A. W. (1999) Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. *J. Immunol.* **162**, 577–584

21. Loetscher, P., Seitz, M., Clark-Lewis, I., Baggioinini, M., and Moser, B. (1994) Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes. *FASEB J.* **8**, 1055–1060

22. Kim, B., Lee, Y., Kim, E., Kwak, A., Ryoo, S., Bae, S. H., Azam, T., Kim, S., and Dinarello, C. A. (2013) The interleukin-1α precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines. *Front. Immunol.* **4**, 391

23. Martinon, F., Burns, K., and Tschopp, J. (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. *Mol. Cell* **10**, 417–426

24. Netea, M. G., Nold-Petry, C. A., Nold, M. F., Joosten, L. A., Opitz, B., van der Meer, J. W., van de Veerdonk, F. L., Ferwerda, G., Heinhuis, B., Devesa, L., Funk, C. J., Mason, R. J., Kullberg, B. J., Rubartelli, A., van der Meer, J. W., and Dinarello, C. A. (2009) Differential requirement for the activation of the inflammasome for processing and release of IL-1β in monocytes and macrophages. *Blood* **113**, 2324–2335

25. Tellides, G. (2006) Th1 adaptive immune responses in cardiac graft atherosclerosis: deleterious or beneficial? *Circulation* **114**, 1561–1564